Overall, impairment of the TLR7/MyD88/IRAK-4 pathway prevents pDCs from producing sufficient type I IFN in response to SARS-CoV-2 in the respiratory tract, accounting for the patients’ vulnerability to infections with this virus. Here, MYD88 is linked to infection.